Plain-English translation of NCT05515367 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a safety study of a medication called , which is designed to treat anemia (low red blood cell count) in people with chronic kidney disease. The study will follow about 1,000 people for one year to make sure the medication is safe and to monitor how well it works in real-world conditions. Researchers want to understand how this treatment performs when used by patients both on and off dialysis.
Many people with chronic kidney disease develop anemia because their kidneys cannot produce enough of a hormone that helps make red blood cells. This medication offers a new way to help treat that anemia, and the study exists to confirm it is safe for long-term use.
You likely qualify if…
You likely don't qualify if…
Over 52 weeks (one year), you would take as an oral tablet at home as directed. You will have regular clinic visits to check your blood hemoglobin levels, monitor for any side effects, and ensure the medication is working safely. The study tracks approximately 1,000 participants—about half on dialysis and half not on dialysis—to see how the treatment works in real everyday conditions.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
India